On February 5, 2026, the New Zealand Court of Appeal issued a crucial judgment in the highly polarized arena of transgender healthcare law. In Professional Association for Transgender Health Aotearoa (PATHA) v Minister of Health NZCA 8, the appellate court dismissed an appeal regarding interim orders that had effectively suspended a government ban on puberty blockers.
The legal conflict stems from the November 2025 promulgation of the Medicines (Restriction on Prescribing Gonadotropin-releasing Hormone Analogues) Amendment Regulations 2025. These regulations, issued via an Order in Council, made it illegal to initiate new prescriptions of puberty blockers for children or adolescents experiencing gender dysphoria. PATHA immediately filed for a judicial review, arguing the regulations were unlawful, and secured an urgent High Court injunction to halt the ban's implementation pending the full trial.
However, PATHA subsequently appealed to the Court of Appeal, expressing concern that the High Court's interim relief was "ineffective". Their counsel argued that because the ban technically remained on the statute books (even if unenforced by the Crown), medical professionals who continued to prescribe the blockers could face private prosecutions or professional misconduct complaints from anti-trans activists alleging ethical breaches.
The Court of Appeal dismissed the appeal but did so by robustly affirming the protective scope of the High Court's original order. The Justices ruled that it would be "extraordinary" for any regulatory body or medical council to facilitate a professional complaint against a doctor based on a law that the High Court has explicitly suspended. The Court declared that allowing private prosecutions under these circumstances would be an "unduly narrow and technical interpretation of the rule of law". This judgment effectively shields healthcare providers from vigilante legal harassment and ensures uninterrupted care for patients.